Know AML webinar | How can physicians and patients communicate more clearly about mutation testing in AML going forward?
This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content. Know AML hoste...
19 Jun 20259min
Know AML webinar | Empowering patients to ask their physician the right questions during their AML journey
Know AML hosted a webinar for patients and healthcare professionals (HCPs) on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share a discussion between Gail J. Roboz...
13 Jun 202527min
Know AML webinar | What are mutations, and why do they matter in AML?
Know AML hosted a webinar for patients and healthcare professionals (HCPs) on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share a presentation by the chair, Charl...
9 Jun 202513min
“How I treat” a patient with DNMT3A-mutated AML in remission post intensive chemotherapy
The AML Hub was pleased to speak with Cristina Papayannidis, Universitaria di Bologna, Bologna, IT. We asked, How do you treat a patient with DNMT3A-mutated acute myeloid leukemia (AML) in remission p...
3 Okt 20245min
CPX-351 as first-line treatment in AML: Real-world data
Here, we summarize five real-world studies presented at EHA 2024 on real-world outcomes of patients with AML who received CPX-351 as a first-line treatment. Hosted on Acast. See acast.com/privacy fo...
30 Sep 202416min
What is the impact of the 5th WHO classification and ICC of AML on diagnosis and treatment of high-risk AML?
The AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What is the impact of the 5th World Health Organization (WHO) classification and International Consens...
17 Sep 202413min
What were your highlights from ASH 2023?
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Michal Bar-Natan, Weill Cornell Medicine, New York, US, shared her highlights with the AML Hub. Hosted on Acast. Se...
29 Apr 20243min
What are the challenges associated with CAR T-cell therapy in patients with AML?
During the 6th European CAR T-Cell Meeting, the AML Hub spoke to Sarah Tettamanti, Tettamanti Foundation Research Center, Monza, IT. We asked, What are the challenges associated with CAR T-cell therap...
25 Apr 20249min
